In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peregrine sinks on latest Phase II data for bavituximab in pancreatic cancer

This article was originally published in Scrip

Executive Summary

Peregrine Pharmaceuticals' stock closed down 19.9% at $1.69 per share on 13 February after the company reported new efficacy results for bavituximab, a monoclonal antibody targeting phosphatidylserine (PS), in a Phase II clinical trial with 70 pancreatic cancer patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC020377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel